Antithrombin III

Drug Profile

Antithrombin III

Alternative Names: Antithrombin-III; Antithrombin-III-alpha; Athimbin; BI51.017; Kybernin; Kybernin P; Neuart

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator CSL Behring
  • Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics
  • Mechanism of Action Blood coagulation factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombosis
  • Preregistration Toxaemia
  • Discontinued Septic shock

Most Recent Events

  • 30 Dec 2015 Preregistration for Toxaemia in Japan (IV) prior to December 2015 (Kaketsuken pipeline, December 2015)
  • 09 Aug 2013 Biomarkers information updated
  • 01 Nov 2007 Regulatory review is ongoing for Toxaemia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top